Jacob McGee1, Vasily Giannakeas2, Beth Karlan3, Jan Lubinski4, Jacek Gronwald4, Barry Rosen5, John McLaughlin6, Harvey Risch7, Ping Sun2, William D Foulkes8, Susan L Neuhausen9, Joanne Kotsopoulos10, Steven A Narod11. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Western University, London, ON, Canada. 2. Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada. 3. Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA. 4. International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. 5. Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, ON, Canada; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Main Floor Room 719, 610 University Ave, Toronto, ON, Canada. 6. Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Joseph & Wolf Lebovic Health Complex, 600 University Avenue, Toronto, ON, Canada; Public Health Ontario, Toronto, ON, Canada. 7. Department of Chronic Disease Epidemiology, Yale School of Public Health, 60 College St., New Haven, CT, USA. 8. Program in Cancer Genetics, Department of Oncology and Human Genetics, McGill University, Montréal, QC, Canada. 9. Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. 10. Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, 155 College Street Health Science Building, 6th Floor, Toronto, ON, Canada. 11. Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, 155 College Street Health Science Building, 6th Floor, Toronto, ON, Canada. Electronic address: steven.narod@wchospital.ca.
Abstract
OBJECTIVE: Preventive breast surgery and MRI screening are offered to unaffected BRCA mutation carriers. The clinical benefit of these two modalities has not been evaluated among mutation carriers with a history of ovarian cancer. Thus, we sought to determine whether or not BRCA mutation carriers with ovarian cancer would benefit from preventive mastectomy or from MRI screening. METHODS: First, the annual mortality rate for ovarian cancer patients was estimated for a cohort of 178 BRCA mutation carriers from Ontario, Canada. Next, the actuarial risk of developing breast cancer was estimated using an international registry of 509 BRCA mutation carriers with ovarian cancer. A series of simulations was conducted to evaluate the reduction in the probability of death (from all causes) associated with mastectomy and with MRI-based breast surveillance. Cox proportional hazards models were used to evaluate the impacts of mastectomy and MRI screening on breast cancer incidence as well as on all-cause mortality. RESULTS: Twenty (3.9%) of the 509 patients developed breast cancer within ten years following ovarian cancer diagnosis. The actuarial risk of developing breast cancer at ten years post-diagnosis, conditional on survival from ovarian cancer and other causes of mortality was 7.8%. Based on our simulation results, among all BRCA mutation-carrying patients diagnosed with stage III/IV ovarian cancer at age 50, the chance of dying before age 80 was reduced by less than 1% with MRI and by less than 2% with mastectomy. Greater improvements in survival with MRI or mastectomy were observed for women who had already survived 10years after ovarian cancer, and for women with stage I or II ovarian cancer. CONCLUSIONS: Among BRCA mutation-carrying ovarian cancer patients without a personal history of breast cancer, neither preventive mastectomy nor MRI screening is warranted, except for those who have survived ovarian cancer without recurrence for ten years and for those with early stage ovarian cancer.
OBJECTIVE: Preventive breast surgery and MRI screening are offered to unaffected BRCA mutation carriers. The clinical benefit of these two modalities has not been evaluated among mutation carriers with a history of ovarian cancer. Thus, we sought to determine whether or not BRCA mutation carriers with ovarian cancer would benefit from preventive mastectomy or from MRI screening. METHODS: First, the annual mortality rate for ovarian cancerpatients was estimated for a cohort of 178 BRCA mutation carriers from Ontario, Canada. Next, the actuarial risk of developing breast cancer was estimated using an international registry of 509 BRCA mutation carriers with ovarian cancer. A series of simulations was conducted to evaluate the reduction in the probability of death (from all causes) associated with mastectomy and with MRI-based breast surveillance. Cox proportional hazards models were used to evaluate the impacts of mastectomy and MRI screening on breast cancer incidence as well as on all-cause mortality. RESULTS: Twenty (3.9%) of the 509 patients developed breast cancer within ten years following ovarian cancer diagnosis. The actuarial risk of developing breast cancer at ten years post-diagnosis, conditional on survival from ovarian cancer and other causes of mortality was 7.8%. Based on our simulation results, among all BRCA mutation-carrying patients diagnosed with stage III/IV ovarian cancer at age 50, the chance of dying before age 80 was reduced by less than 1% with MRI and by less than 2% with mastectomy. Greater improvements in survival with MRI or mastectomy were observed for women who had already survived 10years after ovarian cancer, and for women with stage I or II ovarian cancer. CONCLUSIONS: Among BRCA mutation-carrying ovarian cancerpatients without a personal history of breast cancer, neither preventive mastectomy nor MRI screening is warranted, except for those who have survived ovarian cancer without recurrence for ten years and for those with early stage ovarian cancer.
Authors: Danielle A Henry; Marie C Lee; Deanna Almanza; Kamran A Ahmed; Weihong Sun; David C Boulware; Christine Laronga Journal: Breast Cancer Res Treat Date: 2018-11-24 Impact factor: 4.872
Authors: Koji Matsuo; Rachel S Mandelbaum; Hiroko Machida; Kosuke Yoshihara; Shinya Matsuzaki; Maximilian Klar; Franco M Muggia; Lynda D Roman; Jason D Wright Journal: Arch Gynecol Obstet Date: 2020-03-23 Impact factor: 2.344
Authors: Giulia Tasca; Maria Vittoria Dieci; Zora Baretta; Giovanni Faggioni; Marco Montagna; Maria Ornella Nicoletto; Fedro Alessandro Peccatori; Valentina Guarneri; Nicoletta Colombo Journal: Front Oncol Date: 2020-12-14 Impact factor: 6.244